Emilio Bajetta

26.3k total citations · 6 hit papers
325 papers, 16.6k citations indexed

About

Emilio Bajetta is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Emilio Bajetta has authored 325 papers receiving a total of 16.6k indexed citations (citations by other indexed papers that have themselves been cited), including 210 papers in Oncology, 111 papers in Pulmonary and Respiratory Medicine and 66 papers in Epidemiology. Recurrent topics in Emilio Bajetta's work include Colorectal Cancer Treatments and Studies (59 papers), Neuroendocrine Tumor Research Advances (55 papers) and Cancer Treatment and Pharmacology (54 papers). Emilio Bajetta is often cited by papers focused on Colorectal Cancer Treatments and Studies (59 papers), Neuroendocrine Tumor Research Advances (55 papers) and Cancer Treatment and Pharmacology (54 papers). Emilio Bajetta collaborates with scholars based in Italy, United States and Switzerland. Emilio Bajetta's co-authors include Roberto Buzzoni, Maria Di Bartolomeo, Sergio Bracarda, Nicoletta Zilembo, Bernard Escudier, Alain Ravaud, Bohuslav Melichar, Gianni Bonadonna, Antonia Martinetti and Luigi Celio and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Emilio Bajetta

317 papers receiving 15.9k citations

Hit Papers

Bevacizumab plus interferon alfa... 1976 2026 1992 2009 2007 2009 1976 2001 1998 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
    2007 1.7k citations Bernard Escudier, A Płużańska et al. The Lancet profile →
  2. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
    2009 1.0k citations Emilio Bajetta et al. The Lancet profile →
  3. Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer
    1976 963 citations Gianni Bonadonna, Gabriele Tancini et al. profile →
  4. Effects of Epoetin Alfa on Hematologic Parameters and Quality of Life in Cancer Patients Receiving Nonplatinum Chemotherapy: Results of a Randomized, Double-Blind, Placebo-Controlled Trial
    2001 792 citations Emilio Bajetta et al. Journal of Clinical Oncology profile →
  5. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
    1998 786 citations Eric Van Cutsem, Emilio Bajetta et al. The Lancet profile →
  6. Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival
    2010 632 citations Bernard Escudier, Emilio Bajetta et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Emilio Bajetta Italy 55 10.4k 5.8k 3.9k 3.7k 2.4k 325 16.6k
Yoshitaka Fujii Japan 58 8.3k 0.8× 9.1k 1.5× 7.7k 2.0× 4.0k 1.1× 1.2k 0.5× 439 19.9k
Allan T. van Oosterom Belgium 32 9.3k 0.9× 10.1k 1.7× 4.5k 1.2× 2.8k 0.8× 1.6k 0.7× 89 21.9k
Joel Picus United States 55 9.3k 0.9× 9.2k 1.6× 4.2k 1.1× 4.6k 1.3× 1.5k 0.6× 224 18.1k
Hedy L. Kindler United States 61 8.4k 0.8× 7.3k 1.3× 3.6k 0.9× 3.1k 0.8× 1.2k 0.5× 400 16.1k
Alan P. Venook United States 67 9.8k 0.9× 3.8k 0.7× 3.1k 0.8× 3.0k 0.8× 3.5k 1.5× 365 17.5k
David P. Kelsen United States 72 8.9k 0.9× 6.3k 1.1× 3.1k 0.8× 1.9k 0.5× 1.7k 0.7× 292 14.6k
Patrick Schöffski Belgium 68 9.6k 0.9× 9.5k 1.6× 4.8k 1.2× 2.2k 0.6× 1.5k 0.6× 510 19.4k
Jordan Berlin United States 60 15.3k 1.5× 6.3k 1.1× 6.6k 1.7× 5.0k 1.4× 2.0k 0.8× 357 22.9k
Terry L. Smith United States 65 7.7k 0.7× 2.6k 0.5× 2.8k 0.7× 4.2k 1.1× 989 0.4× 154 16.0k
Paul Elson United States 60 4.7k 0.5× 5.6k 1.0× 4.5k 1.1× 2.6k 0.7× 1.5k 0.6× 334 13.4k

Countries citing papers authored by Emilio Bajetta

Since Specialization
Citations

This map shows the geographic impact of Emilio Bajetta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emilio Bajetta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emilio Bajetta more than expected).

Fields of papers citing papers by Emilio Bajetta

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emilio Bajetta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emilio Bajetta. The network helps show where Emilio Bajetta may publish in the future.

Co-authorship network of co-authors of Emilio Bajetta

This figure shows the co-authorship network connecting the top 25 collaborators of Emilio Bajetta. A scholar is included among the top collaborators of Emilio Bajetta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emilio Bajetta. Emilio Bajetta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bajetta, Emilio, Laura Catena, Sara Pusceddu, et al.. (2017). Everolimus in Combination with Octreotide Long-Acting Repeatable in a First-Line Setting for Patients with Neuroendocrine Tumors: A 5-Year Update. Neuroendocrinology. 106(4). 307–311. 16 indexed citations
2.
Strosberg, Jonathan, James C. Yao, Emilio Bajetta, et al.. (2015). Efficacy of Octreotide Long-Acting Repeatable (OCT) From the Phase III RADIANT-2 Study in Patients With Advanced Neuroendocrine Tumors (NET) : A Post-Hoc Analysis of the Placebo (PBO) Arm With Updated Survival Data. Pancreas. 44(2). 359–359. 1 indexed citations
3.
Bartolomeo, Maria Di, Alessandro Pellegrinelli, Roberto Iacovelli, et al.. (2015). Association with programmed death ligand-1 (PDL-1) expression and Helicobacter Pylori infection in patients with non-diffuse type gastric carcinoma. Annals of Oncology. 26. vi93–vi93. 2 indexed citations
4.
Martinetti, Antonia, Rosalba Miceli, Elisa Sottotetti, et al.. (2014). Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens. Cancers. 6(3). 1753–1768. 16 indexed citations
5.
Altomonte, Maresa, Anna Maria Di Giacomo, Paola Queirolo, et al.. (2013). Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme. Journal of Experimental & Clinical Cancer Research. 32(1). 82–82. 20 indexed citations
6.
Maio, Michele, Paolo A. Ascierto, Alessandro Testori, et al.. (2012). The cost of unresectable stage III or stage IV melanoma in Italy. Journal of Experimental & Clinical Cancer Research. 31(1). 91–91. 26 indexed citations
7.
Vecchio, Michele Del, Roberta Mortarini, Stefania Canova, et al.. (2010). Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors. Clinical Cancer Research. 16(23). 5862–5872. 44 indexed citations
8.
Cortinovis, Diego, Francesca Andriani, Alessandra Fabbri, et al.. (2008). FHIT and p53 Status and Response to Platinum-Based Treatment in Advanced Non-Small Cell Lung Cancer. Current Cancer Drug Targets. 8(5). 342–348. 10 indexed citations
9.
Pusceddu, Sara, Emilio Bajetta, Roberto Buzzoni, et al.. (2008). Primary Uterine Cervix Melanoma Resembling Malignant Peripheral Nerve Sheath Tumor: A Case Report. International Journal of Gynecological Pathology. 27(4). 596–600. 13 indexed citations
10.
Sartore‐Bianchi, Andrea, Mauro Moroni, Silvio Veronese, et al.. (2007). Epidermal Growth Factor Receptor Gene Copy Number and Clinical Outcome of Metastatic Colorectal Cancer Treated With Panitumumab. Journal of Clinical Oncology. 25(22). 3238–3245. 264 indexed citations
11.
Bajetta, Emilio, Marco Platania, Laura Catena, et al.. (2007). MERKEL CELL CARCINOMAAFTER LIVER TRANSPLANTATION: A CASE REPORT. Tumori. 97(3). 323–326. 1 indexed citations
12.
Cutsem, Eric Van, Salvatore Siena, Yves Humblet, et al.. (2007). An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Annals of Oncology. 19(1). 92–98. 128 indexed citations
13.
Escudier, Bernard, A Płużańska, P. Koralewski, et al.. (2007). Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. The Lancet. 370(9605). 2103–2111. 1722 indexed citations breakdown →
14.
Bartolomeo, Maria Di, Roberto Buzzoni, Luigi Mariani, et al.. (2006). Feasibility of Sequential Therapy with FOLFIRI Followed by Docetaxel/Cisplatin in Patients with Radically Resected Gastric Adenocarcinoma. Oncology. 71(5-6). 341–346. 11 indexed citations
15.
Brandi, Giovanni, Maria A. Pantaleo, Carlo Calabrese, et al.. (2004). Complete remission of primary colon cancer in a metastatic patient treated with CPT-11 plus capecitabine. International Journal of Colorectal Disease. 19(6). 599–602. 4 indexed citations
16.
Bajetta, Emilio, Simonetta Chiara Stani, Nadia Zaffaroni, et al.. (2003). Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IVnon-small-cell lung cancer. Annals of Oncology. 14(2). 242–247. 15 indexed citations
17.
Leo, Angelo Di, Emilio Bajetta, Laura Biganzoli, et al.. (1995). An I.T.M.O. group study on second-line treatment in advanced epithelial ovarian cancer: an attempt to identify clinical and biological factors determining prognosis. European Journal of Cancer. 31(13-14). 2248–2254. 11 indexed citations
18.
Bajetta, Emilio, Marco Colleoni, Maria Di Bartolomeo, et al.. (1995). Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer.. Journal of Clinical Oncology. 13(10). 2613–2619. 37 indexed citations
19.
Bajetta, Emilio, Nicoletta Zilembo, Maria Di Bartolomeo, et al.. (1993). Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a: A study by the Italian trials in Medical Oncology Group. Cancer. 72(10). 3099–3105. 107 indexed citations
20.
Bonadonna, Gianni, Gabriele Tancini, & Emilio Bajetta. (1976). Controlled studies with bleomycin in solid tumors and lymphomas.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 11. 172–84. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yoshitaka Fujii Breakdown of academic impact, for papers by Allan T. van Oosterom Breakdown of academic impact, for papers by Joel Picus Breakdown of academic impact, for papers by Hedy L. Kindler Breakdown of academic impact, for papers by Alan P. Venook Breakdown of academic impact, for papers by David P. Kelsen Breakdown of academic impact, for papers by Patrick Schöffski Breakdown of academic impact, for papers by Jordan Berlin Breakdown of academic impact, for papers by Terry L. Smith Breakdown of academic impact, for papers by Paul Elson
Rankless by CCL
2026